Vaniprevir

Source: Wikipedia, the free encyclopedia.
Vaniprevir
Names
IUPAC name
(1R,21S,24S)-21-tert-Butyl-N-((1R,2R)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-ethylcyclopropyl)-16,16-dimethyl-3,19,22-trioxo-2,18-dioxa-4,20,23-triazatetracyclo[21.2.1.14,7.06,11]-heptacosa-6,8,10-triene-24-carboxamide
Identifiers
3D model (
JSmol
)
ChEBI
ChEMBL
ChemSpider
DrugBank
ECHA InfoCard
100.207.830 Edit this at Wikidata
EC Number
  • 682-506-7
KEGG
UNII
  • InChI=1S/C38H55N5O9S/c1-7-25-18-38(25,33(46)41-53(49,50)27-14-15-27)40-31(44)29-17-26-20-43(29)32(45)30(36(2,3)4)39-34(47)51-22-37(5,6)16-9-8-11-23-12-10-13-24-19-42(21-28(23)24)35(48)52-26/h10,12-13,25-27,29-30H,7-9,11,14-22H2,1-6H3,(H,39,47)(H,40,44)(H,41,46)/t25-,26-,29+,30-,38-/m1/s1
    Key: KUQWGLQLLVFLSM-ONAXAZCASA-N
  • CC(C)(C)[C@H]1NC(=O)OCC(C)(C)CCCCc2cccc3CN(Cc23)C(=O)O[C@H]4C[C@@H](N(C4)C1=O)C(=O)N[C@@]5(C[C@H]5C=C)C(=O)NS(=O)(=O)C6CC6
Properties
C38H55N5O9S
Molar mass 757.94 g·mol−1
Appearance White powder
Hazards
GHS labelling:
GHS08: Health hazard
Warning
H373
P260, P314, P501
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

Vaniprevir (MK-7009) is a

4A protease inhibitor, developed by Merck & Co., which is currently in clinical testing.[1] In Japan, it was approved for treating hepatitis C in 2014 under the brand name Vanihep.[2][3]

References

  1. .
  2. ^ "First recommendation for HCV drug vaniprevir, in Japan". datamonitorhealthcare.com. September 25, 2014.
  3. ^ "New Drugs Approved" (PDF). Pharmaceuticals and Medical Devices Agency. {{cite journal}}: Cite journal requires |journal= (help)